The latest coronavirus developments and scientific research on prevention and treatment.
Mateon Therapeutics Inc.announced it has submitted an Investigational New Drug (IND) application to the FDA)to study its investigational drug, OT-101, for the treatment of COVID-19 pandemic.The proposed randomized,… read more.
Myovant Sciences announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety findings from the Phase III LIBERTY 1 and 2 studies… read more.
BioNTech AG and Pfizer Inc. have announced that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 1/II clinical trial for BioNTech’s BNT 162 vaccine program to… read more.
Siemens Healthineers announced it is significantly expanding its infectious disease testing capabilities to aid in the COVID-19 pandemic. Recognizing the critical need for accurate diagnostic testing to manage… read more.
Vela Diagnostics announced that the manual version of the ViroKey SARS-CoV-2 RT-PCR Test has received the CE mark for in vitro diagnostic use. The test detects SARS-CoV-2 in… read more.
AstraZeneca and Saint Luke’s Mid America Heart Institute have initiated a randomised, global Phase III trial to assess the potential of Farxiga (dapagliflozin) as a treatment in patients… read more.
The Population Health Research Institute (PHRI) and Bayer Canada Inc. announced plans to immediately launch a major clinical research program aimed at identifying potential COVID-19 treatments. The two… read more.
EASE Trial of AP 101 from Amryt Pharma Update: In recent weeks, the COVID-19 pandemic has had a material impact on clinical trials globally, including patient recruitment. Given… read more.
Seegene, Inc. announced that U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its Allplex 2019-nCoV Assay, a Real-time RT-PCR test for SARS-CoV-2, the novel… read more.
Alexion Pharmaceuticals, Inc.announced plans to initiate a global Phase III study to investigate Ultomiris (ravulizumab-cwvz) in a subset of adults with COVID-19 – those who are hospitalized with… read more.
Novartis announced new Mayzent (siponimod) data in the April supplemental issue of Neurology, the medical journal of the American Academy of Neurology. The data build on existing clinical… read more.
Novartis has reached an agreement with the FDA to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
